# Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

> **NCT03788759** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara** · enrollment: 48 (actual)

## Conditions studied

- Schizophrenia
- Oxidative Stress

## Interventions

- **DRUG:** Alpha-lipoic acid
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03788759
- **Lead sponsor:** Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03788759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03788759, "Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03788759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*